Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical: Progression‐free survival
Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Progression free survival (median 2 years) · patients with chronic lymphocytic leukaemia Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty). Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane Headline outcomes only | HR 0.61 [0.47, 0.81] | 2 studies · 356 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Alemtuzumab for patients with chronic lymphocytic leukaemia 2012 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.